Literature DB >> 15012689

Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea.

Ho Yung Lee1, Beom Seok Kim, Hoon Young Choi, Hyeong Cheon Park, Shin Wook Kang, Kyu Hun Choi, Sung Kyu Ha, Dae Suk Han.   

Abstract

Sclerosing encapsulating peritonitis (SEP) is a rare yet serious complication in patients with continuous ambulatory peritoneal dialysis (CAPD). Incidence and prevalence of this syndrome have been defined in some large populations and a few single-centre experiences, but there is no satisfactory estimate of the comparative incidence of dialysis related SEP. The pathogenesis of SEP still remains uncertain, but there could be various causative factors. The diagnosis of SEP remains based on clinical suspicion confirmed with radiologic and/or pathologic findings. The possible variable etiologies and probable distinct pathways leading to this syndrome may make a uniform therapeutic approach unlikely. To determine the prevalence, etiologic factors, clinical features, effect of dialysis duration, and outcome of SEP in Korea, patients undergoing CAPD who developed SEP were retrospectively studied in five University Hospital dialysis centres with large numbers of CAPD patients in Korea. Out of a total 3888 CAPD studied patients between January 1981 to December 2002 in those five medical centres, 31 cases developed SEP with the overall prevalence 0.8%. There were 15 men and 16 women. The mean age of these patients was 44.0 +/- 9.8 years old. The mean duration of CAPD before SEP was 70.3 +/- 41.9 months (range 9-144 months) and 67.8% of patients (21/31) had been on CAPD more than 4 years. Peritonitis, including one fungal peritonitis, was the main cause of SEP in 25 cases (80.6%). Seventy percent of these cases used beta-blocker and the mean duration of the usage was 61.7 +/- 47.6 months. Seven cases were surgically treated and others were treated conservatively with intermittent total parenteral nutrition. The mortality rate was 25.8%. In conclusion, SEP is a serious life threatening complication of CAPD, and most cases had long-term peritoneal dialysis (PD) duration more than 4 years. To reduce the incidence of SEP, careful monitoring may be needed especially in patients with long-term CAPD and peritonitis.

Entities:  

Mesh:

Year:  2003        PMID: 15012689     DOI: 10.1046/j.1440-1797.8.s.11.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  16 in total

1.  No need for an "expiry date" in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis.

Authors:  Guido Garosi; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

2.  Old and new perspectives on peritoneal dialysis in Italy emerging from the Peritoneal Dialysis Study Group Census.

Authors:  Giancarlo Marinangeli; Gianfranca Cabiddu; Loris Neri; Giusto Viglino; Roberto Russo; Ugo Teatini
Journal:  Perit Dial Int       Date:  2012-03-01       Impact factor: 1.756

3.  Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study.

Authors:  Erika De Sousa-Amorim; Gloria Del Peso; M Auxiliadora Bajo; Laura Alvarez; Marta Ossorio; Fernando Gil; Teresa Bellon; Rafael Selgas
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

4.  Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study.

Authors:  Masaaki Nakayama; Masanobu Miyazaki; Kazuho Honda; Kenji Kasai; Tadashi Tomo; Hidetomo Nakamoto; Hideki Kawanishi
Journal:  Perit Dial Int       Date:  2014-02-04       Impact factor: 1.756

5.  Encapsulating peritoneal sclerosis in the new millennium: a national cohort study.

Authors:  Michaela C Brown; Keith Simpson; Jan J Kerssens; Robert A Mactier
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

6.  Encapsulating peritoneal sclerosis: case series from a university center.

Authors:  Kyung-Deuk Hong; Ji Hea Bae; Yun-Jin Jang; Hee-Yeon Jung; Jang-Hee Cho; Ji-Young Choi; Chan-Duck Kim; Yong-Lim Kim; Sun-Hee Park
Journal:  Korean J Intern Med       Date:  2013-08-14       Impact factor: 2.884

7.  Incidence and outcome of encapsulating peritoneal sclerosis.

Authors:  Michaela C Petrie; Jamie P Traynor; Robert A Mactier
Journal:  Clin Kidney J       Date:  2016-06-20

8.  Sclerosing encapsulating peritonitis (abdominal cocoon) after abdominal hysterectomy.

Authors:  Won Na Suh; Sang Kil Lee; Hyun Chang; Hye Jin Hwang; Woo Jin Hyung; Young Nyun Park; Tae Il Kim
Journal:  Korean J Intern Med       Date:  2007-06       Impact factor: 2.884

9.  Nutrition changes in conservatively treated patients with encapsulating peritoneal sclerosis.

Authors:  Nevine El-Sherbini; Neill Duncan; Mary Hickson; Lina Johansson; Edwina A Brown
Journal:  Perit Dial Int       Date:  2013-07-01       Impact factor: 1.756

10.  Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients.

Authors:  Mitsuhiro Tawada; Yasuhiko Ito; Chieko Hamada; Kazuho Honda; Masashi Mizuno; Yasuhiro Suzuki; Fumiko Sakata; Takeshi Terabayashi; Yoshihisa Matsukawa; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Yoshifumi Takei
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.